What question did this study set out to answer?

To develop and validate a model predicting pathologic complete response (pCR) based on early changes in absolute lymphocyte count during neoadjuvant therapy in HER2+ breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS3-10-30: A clinical model to predict pathologic complete response using early peripheral absolute lymphocyte dynamics in HER2+ breast cancer

View Full Paper

Ask AI

Bookmark

Authors

CBColin P. BergstromStanford Medicine ILIngrid LuoPalo Alto University EKE. KotlerStanford Medicine

Discussion

Member takes

Implication

This clinical model predicts pathologic complete response in HER2+ breast cancer, suggesting early response assessment via lymphocyte changes.

Key Points

To develop and validate a model predicting pathologic complete response (pCR) based on early changes in absolute lymphocyte count during neoadjuvant therapy in HER2+ breast cancer.
Analyzed a retrospective cohort of HER2+ breast cancer patients on trastuzumab-based neoadjuvant therapy.
Constructed a multivariable logistic regression model to identify predictors of pCR.
Developed a composite risk score using baseline absolute lymphocyte count and early ALC change.
Used receiver operating characteristic curve analysis to evaluate model performance.
Validated the model in a separate cohort of patients undergoing NAT.
In the discovery cohort, higher baseline ALC and greater ALC decline correlated with higher pCR odds.
The ALC risk score categorized patients into low, intermediate, and high pCR probability groups with observed rates of 15%, 51%, and 76%.
The model demonstrated an AUC of 0.81 in both discovery and validation cohorts, indicating strong predictive ability.

Cite This Study

Bergstrom et al. (2026) studied this question.

synapsesocial.com/papers/6996a85cecb39a600b3eefc9 https://doi.org/10.1158/1557-3265.sabcs25-ps3-10-30

View Full Paper

Ask AI

Bookmark

Implication

This clinical model predicts pathologic complete response in HER2+ breast cancer, suggesting early response assessment via lymphocyte changes.

Abstract PS3-10-30: A clinical model to predict pathologic complete response using early peripheral absolute lymphocyte dynamics in HER2+ breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS3-10-30: A clinical model to predict pathologic complete response using early peripheral absolute lymphocyte dynamics in HER2+ breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider